About

ZOMIG

ZOMIG provides speed, power, and versatility across 3 formulations that are proven to provide clinical efficacy.

This section provides important data about all 3 formulations of ZOMIG. You will see how each formulation treats migraine headaches with speed, power, and versatility to bring the migraine relief your patients need.

The Speed: FAST HEADACHE RESPONSE

All 3 formulations of ZOMIG have the speed to provide rapid migraine relief.

The Power: PAIN-FREE RESPONSE

All 3 formulations of ZOMIG have the power to deliver a pain-free response by reducing migraine pain from severe or moderate in intensity to a state of no pain.

The Versatility: FORMULATION OPTIONS

ZOMIG has the versatility of multiple administration options that will accommodate virtually any migraine treatment program or patient preference.

Indication and Important Safety Considerations

ZOMIG (zolmitriptan) is indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established
ZOMIG, like other compounds in this class, should not be given to patients with coronary artery disease (CAD) or for whom unrecognized CAD is predicted by risk factors or to patients with uncontrolled hypertension
ZOMIG should not be administered to patients with hemiplegic or basilar migraine
ZOMIG should not be given to patients with cerebrovascular syndromes including (but not limited to) stroke of any type as well as transient ischemic attacks
The development of a potentially life-threatening serotonin syndrome may occur with triptans, including ZOMIG treatment, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)
There are no adequate and well-controlled studies in pregnant women; therefore ZOMIG should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
The most common adverse events in clinical trials for ZOMIG and ZOMIG-ZMT were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation
The most common adverse events in clinical trials for ZOMIG Nasal Spray were unusual taste, paresthesia, hyperesthesia, and dizziness
Phenylketonuric patients should be informed that ZOMIG-ZMT 2.5 mg and ZOMIG-ZMT 5 mg contain 2.81 and 5.62 mg of phenylalanine (a component of aspartame), respectively

ZOMIG and ZOMIG-ZMT are registered trademarks of the AstraZeneca group of companies. This product information is intended for US health care professionals only.

This product information is intended for
US health care professionals only.